<DOC>
	<DOCNO>NCT00488865</DOCNO>
	<brief_summary>This study design evaluate safety efficacy RexMedical Option* Vena Cava Filter treatment patient increase risk Pulmonary Embolism require caval interruption .</brief_summary>
	<brief_title>RexMedical- Option* Vena Cava Filter IDE Study</brief_title>
	<detailed_description />
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<criteria>Key Patient least 18 year age Patient require temporary permanent caval interruption Key Patient preexist filter implant her/her vasculature undergone filter retrieval within 60 day prior study device implant Patient currently enrol another investigational device drug trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>increase risk PE require caval interruption</keyword>
</DOC>